NCT03416933View on ClinicalTrials.gov

Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 27, 2018

Primary Completion Date

June 17, 2022

Study Completion Date

June 17, 2022

Conditions
Melanoma (Skin)
Interventions
OTHER

Blood sampling

2x10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.

Trial Locations (4)

21079

Centre Georges François Leclerc (CGFL), Dijon

57 100

Hôpital de Mercy, Thionville

54 511

CHRU Nancy, Vandœuvre-lès-Nancy

Unknown

Institut de Cancérologie de Lorraine (ICL), Vandœuvre-lès-Nancy

All Listed Sponsors
lead

Institut de Cancérologie de Lorraine

OTHER

NCT03416933 - Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma | Biotech Hunter | Biotech Hunter